期刊文献+

通脉降糖胶囊对AGEs诱导的雪旺细胞凋亡的影响及机制 被引量:1

Effect of tongmaijiangtang capsule on advanced glycation end products-induced apoptosis and its mechanism in Schwann cells
原文传递
导出
摘要 目的探讨活血化瘀中药通脉降糖胶囊(TM)对雪旺细胞(sC)凋亡的影响及机制。方法采用血清药理学方法制备TM含药血清培养液。切取Wistar大鼠双侧坐骨神经,并经消化、离心、培养获得SC。(1)将SC分成正常对照组、SC+TM共培养组(TM组)、SC+晚期糖基化终末产物(AGEs)共培养组(AGEs组)、SC+TM+AGEs共培养组(TM+AGEs组),培养24h后进行Hoechst33258和S100免疫荧光染色并于荧光显微镜下计数SC。(2)将SC分成正常眦清对照Ⅰ组和TM血清Ⅱ组,培养24h后应用逆转录聚合酶链反应(RT.PCR)检测肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)、脑源性神经营养因子(BDNF)、神经生长因子(NGF)mRNA表达。(3)将SC分成正常血清对照Ⅱ组和TM血清Ⅱ组,培养48h后应用ELISA法检测TNF—α、IL-6蛋白表达。结果(1)与正常对照组(60.1±3.7)相比,TM组SC数量(82.8±3.8)明显增加,AGEs组SC数量(17.1±1.7)明显减少;TM+AGEs组sC数量(42.3±1.6)较AGEs组明显增加,差异均有统计学意义(P〈0.05)。(2)与正常血清对照Ⅰ组相比,TM血清Ⅰ组TNF-α、IL-6mRNA表达量明显降低,BDNF、NG FmRNA表达无明显变化。(3)与正常血清对照Ⅱ组[TNF-α:(54.7±0.2);IL-6:(955.8±6.8)1相比,TM血清Ⅱ组TNF-α、IL-6蛋白表达【TNF-α:(37.9±0.9);IL-6:(861.3±10.2)]明显降低,差异均有统计学意义(P〈0,05)。结论TM可能是通过抑制TNF-α、IL-6表达从而明显抑制AGEs诱发的SC凋亡。 Objective To explore the effect oftongmaijiangtang capsule (TM) on apoptosis and its mechanism in Schwann cells (SCs). Methods The TM contained serum was prepared by using blood serum pharmacological method. Bilateral ischiadic nerves from Wistar rats were sliced, digested and centrifuged to acquire the SCs. (1) These SCs were divided into normal control group, AGEs treatment group, TM treatment group and TM+AGEs treatment group; 24 h after each treatment, the SCs were detected by immunoftuorescent staining using $100 and DNA-specific fluorescent regent Hoechst 33258, and then, the SCs number was compared under fluorescent microscope. (2) SCs were divided into normal control group Ⅰ and TM treatment group Ⅰ; 24 h after treatment, reverse transcription-polymerase chain reaction (RT-PCR) was used to measure the mRNA expressions of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), brain derived neurotrophic factor (BDNF) and nerve growth factor (NGF). (3) SCs were divided into normal control group Ⅱ and TM treatment group Ⅱ; 48 h after treatment, ELISA was employed to detect the protein expressions of TNF-α and IL-6 in SCs. Results (1) As compared with that in the control group (60.1±3.7), the number of SCs in TM treatment group (82.8±3.8) was statistically increased, and that in AGEs treatment group was significantly decreased (17.1 ±1.7, P〈0.05);the number of SCs in TM+AGEs treatment group (42.3±1.6) increased significantly as compared with that in AGEs group (P〈0.05). (2) The mRNA expressions of TNF-α and IL-6 in the TM treatment group Ⅰ obviously decreased as compared with that in the control group I; but those of BDNF and NGF in the TM treatment group I were similar with those in the control group. (3) The protein expressions of TNF-ot and IL-6 in the TM treatment group II (54.7±0.2, 955.8±6.8) were statistically decreased as compared with those in the control group Ⅱ (37.9±0.9, 861.3±10.2, P〈0.05). Conclusion TM could effectively inhibit SCs apoptosis induced by AGEs and significantly decrease the mRNA and protein expressions of TNF-α and IL-6 to reduce the apoptosis of SCs.
出处 《中华神经医学杂志》 CAS CSCD 北大核心 2015年第11期1089-1094,共6页 Chinese Journal of Neuromedicine
基金 国家自然科学基金(8J173424、81373796)
关键词 通脉降糖胶囊 雪旺细胞 糖基化终末产物 肿瘤坏死因子-Α 白介素-6 Tongmaijiangtang capsule Schwann cell Advanced glycation end product Tumor necrosis factor-α Interleukin-6
  • 相关文献

参考文献25

  • 1Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications[J]. Phys Ther, 20(18, 88 (111: 1254.
  • 2Llewelyn JG. The diabetic neuropathies: types, diagnosis and management[J]. J Neurol Neurosurg Psychiatry, 2003, 74 Suppl 2: iil5-iil9.
  • 3Gryz EA, Calicka-Latala D, Szczudlik A, et al. Etiopathogenesis of diabetic neuropathy[J]. Przegl Lek, 2000, 57( 12): 727-731.
  • 4张爱旗,王会芳,李志茹.通脉降糖胶囊治疗糖尿病周围神经病变临床观察[J].现代中西医结合杂志,2012,21(10):1077-1077. 被引量:16
  • 5张良,徐立,袁冬萍,方泰惠.中药血清药理学方法的研究进展[J].南京中医药大学学报,2002,18(4):254-256. 被引量:38
  • 6Tan W, Rouen S, Barkus KM, et al. Nerve growth factor blocks the glucose-induced down-regulation of caveolin-1 expression in Schwann cells via p75 neurotrophin receptor signaling [J]. J Biol Chem, 2003, 278(25): 23151-23162.
  • 7Shettar A, Muttagi G. Developmental regulation of insulin receptorgene in sciatic nerves and role of insulin on glycoprotein PO in the Schwann cells[J]. Peptides, 2012, 36(1): 46-53.
  • 8王青.步长通脉降糖胶囊治疗糖尿病周围神经病变临床观察[J].中外健康文摘.2013,26(10):194-195.
  • 9Stracke H, Hammes HP, Werkmann D, et al. Efficacy of benfotiamine versus thiamine on fimction and glycation products of peripheral nerves in diabetic rats[J]. Exp Clin Endocrinol Diabetes, 2001, 109(6): 330-336.
  • 10Wada R, Nishizawa Y, Yagihashi N, et al. Effects of OPB-9195, anti-glycation agent, on experimental diabetic neuropathy[J]. Eur J Clin Invest, 2001, 31(6): 513-520.

二级参考文献48

  • 1许珊丹,曾婧,陈冠民,李汝霖.神经生长因子在周围神经系统疾病中的临床应用[J].中国新药杂志,2004,13(7):587-589. 被引量:9
  • 2宁光,邹大进,刘伟,刑惠莉,张炜,赵咏桔,鲁瑾,徐华,金杰.神经妥乐平治疗糖尿病神经病变的多中心研究[J].中华医学杂志,2004,84(21):1785-1787. 被引量:39
  • 3张群豪 陈可冀.血清药理学在中药及复方研究中应用的评价[J].中国中西医结合杂志,1996,16(3):131-131.
  • 4王宁生.关于血清药理学的若干思考[J].中国中西医结合杂志,1999,19(5):263-263.
  • 5Siemionow M,Demir Y.Diabetic neuropathy:pathogensis and treatment.J Reconstr Microsurg,2004,20(3):241-252.
  • 6Casellini C M,Vinik A I.Recent advances in the treatment of diabetic neuropathy. Currrent Opinion in Endocrinology and Diabctes,2006,13(2):147-153.
  • 7Tomlinson D R,Fernyhough P,Diemel L T. Role of neurotrophins in diabetic neuropathy and treatment with nerve growth factors. Diabetes,1997,46(Suppl 2):S43-49.
  • 8Apfel S C.Neurotrophic factors in the therapy of diabetic. Am J Med,1999,107(2B):34S-42S.
  • 9Yasuda H, Terada M, Maeda K, et al.Diabetic neuropathy and nerve regeneration. Prog Neurobiol,2003,69(4):229-285.
  • 10Kennedy J M,Zochodne D W.Impaired peripheral nerve regeneration in diabetes mellitus. J Peripher Nerv Syst,2005,10(2):144-157.

共引文献82

同被引文献14

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部